In this webinar, experts from Ardea review the origins of GAS, its value as an endpoint, and recent uses throughout the clinical development cycle from Phase 2 to post-market studies. Panelists will demystify GAS data by unpacking its interpretation in both placebo-controlled trials and real-world evidence studies.
Friday, February 26, 2021 | 11am EST (NA) / 4pm GMT (UK) / 5pm CET (EU-Central) 60 min
Join us for our second webinar in the Ardea Insights Series on Goal Attainment Scaling.
Over the past two decades, Patient Reported Outcome Measures (PROMs) have been increasingly included in clinical development research to capture the patient voice. With recent FDA guidelines on patient-focused drug development (2019) and patient-reported outcome measures (2020), these approaches have firmly entered the mainstream and are now seen as standard elements of any modern trial design. As standardized approaches to PROMs have gained prominence, we have also seen an emergence in trials involving personalized endpoints such as Goal Attainment Scaling (GAS).
Register for this webinar at XTalks to hear Ardea’s experts share knowledge from decades of experience working in Goal Attainment Scaling to guide participants through GAS study design and implementation.
